Overview

Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

Status:
Withdrawn
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if initial therapy with ABLC at 10/mg/kg/d for 7 days are at least effective as ABLC at 5.0 mg/kg/d X 14 days as induction treatment of patients with disseminated cryptococcosis and HIV.
Phase:
Phase 4
Details
Lead Sponsor:
Medstar Health Research Institute
Collaborator:
Enzon Pharmaceuticals, Inc.
Treatments:
Amphotericin B
Liposomal amphotericin B